// App-Quantinova.ai

EP439 : CYTOPENIA MANAGEMENT IN THE PHASE 3 VIALE-C STUDY OF VENETOCLAX PLUS LOW-DOSE CYTARABINE FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE CHEMOTHERAPY

Researchers

Presenter

  • Andrew H. Wei

Principal Investigators

  • Pau Montesinos

  • Vladimir Ivanov

  • Jan? Novak

  • Kamel Laribi

  • Inho Kim

  • Don ?A. Stevens

  • Walter M. Fiedler

  • Julie? Bergeron

  • Jing-Zhou Hou

  • Vidhya Murthy

  • Andrew McDonald

  • Takahiro Yamauchi

  • Kenichi Ishizawa

  • Jianxiang Wang

  • Yinghui Duan

  • Majd T. Ghanim

  • Wellington Mendes

  • Courtney D. DiNardo

Medical Centers

  • Netcare Pretoria East Hospital,Moreleta Park, Pretoria,South Africa

  • Oncology,Norton Cancer Institute,Louisville,United States

  • State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital and Center for Stem Cell Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

  • University of Pittsburgh Medical Center (UPMC) Cancer Center,Pittsburgh,United States

  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Centre Hospitalier du Mans, Le Mans, France

  • Hospital Universitari I Politecnic La Fe, Valencia, Spain

  • CIUSSS-EMTL, Installation Maisonneuve-Rosemont,Montreal,Canada

  • Heartlands Hosp, Birmingham, United Kingdom

  • University of Fukui Hospital,Fukui, Japan,Japan

  • The Alfred Hospital and Monash University, Melbourne, Australia

  • Department of Clinical Hematology, University Hospital Kralovske Vinohrady, Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic

  • National and Kapodistrian University of Athens, Medical School, Laikon General Hospital, Athens, Greece

  • Almazov National Medical Research Centre, Saint‐Petersburg, Russian Federation

  • Chonbuk National University Medical School, Jeonju, Korea, Republic of

  • Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan

  • AbbVie Inc.,North Chicago, United States,United States

  • Hubertus Wald Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Locations

  • South Africa

  • United States

  • China

  • France

  • Spain

  • Canada

  • United Kingdom

  • Japan

  • Australia

  • Czech Republic

  • Greece

  • Russia

  • Republic of South Korea

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Acute myelocytic leukemia

  • Thrombocytopenia

  • Neutropenia

Biomarkers

  • N/A

Drug/Treatment

  • Cytarabine liposomal

  • Venetoclax

Outcome

  • N/A


Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03069352

Sponsors

  • N/A

Result

  • N/A